A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Acalabrutinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Acerta Pharma
- 29 Jun 2016 Status changed from active, no longer recruiting to completed.
- 08 Apr 2016 Planned number of patients changed from 70 to 31 as reported by ClinicalTrilas.gov.
- 08 Apr 2016 Planned primary completion date changed from 1 Jan 2017 to 1 May 2016 as reported by ClinicalTrials.gov.